Latest Regulatory News

Findi Limited’s shares have been suspended from trading on the ASX starting 1 July 2025 due to failure to lodge a required periodic report on time. The suspension will remain until the report is submitted and trading can resume.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Orpheus Uranium has launched a targeted exploration program at its Mt Douglas Project in the Northern Territory, supported by a government co-funding grant and approved permits enabling advanced drilling activities.

Medallion Metals has taken a crucial step by acquiring 258 hectares near Ravensthorpe to meet environmental offset requirements, advancing its gold project approvals under federal law.

Kinetiko Energy has signed a non-binding term sheet with FFS Refiners to co-develop a pilot LNG plant at Brakfontein, aiming to fast-track gas production and supply to South Africa's industrial market.

archTIS Limited has secured A$7.5 million through a discounted share placement to fund expansion in the U.S. defence sector, deepen strategic partnerships, and accelerate product innovation focused on secure data collaboration.

MRG Metals has achieved a pivotal milestone with the granting of the Corridor South 11137 Mining Licence in Mozambique, setting the stage for production within 12 to 18 months under its fully funded Corridor Sands Project.

Betashares Capital Ltd has announced the final distribution amounts for over 70 ETFs for the June 2025 period, detailing payment schedules and reinvestment plan options.

West Cobar Metals has initiated approvals for a 5,000m air core drilling campaign at its promising Mystique Gold Project, aiming to unlock significant gold mineralisation in Western Australia’s Fraser Range.

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.

Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.